Global clinical development pipeline

As of: November 3, 2026

Phase 1

Sonrotoclax — BCL2i
- 101 B-cell malignancies
- 103 MDS
- 105 R/R MM t(11;14)
- 109 B-cell malig. pediatric**

Tacabrutideg — BTK CDAC
- 101/102 B-cell malignancies
- 104 B-cell malignancies
- 107 Chr. spontaneous urticaria

BG-T0050 — CD19xCD20xCD3 tsAb
- 101 B-cell malignancies**

BG-T0920 — BAFFRxCD22xCD3 tsAb
- 101 B-cell malignancies**

BG-C9074[1] — B7-H4 ADC
- 101 Solid tumors

BGB-21447 — BCL2i
- 101 Solid tumors

BG-75098 — CDK2 CDAC
- 101 Solid tumors

BGB-43395 — CDK4i
- 101 Solid tumors

BGB-B455 — CLDN6 x CD3 bsAb
- 101 Solid tumors

BG-75202 — KAT6A/Bi
- 101 Solid tumors
- 102 Myeloid malignancies

BG-C0979 — ADAM9 ADC
- 101 Solid tumors

BON-C1393 — B7-H3xITGB6 bsADC
- 101 Solid tumors**

BG-C477 — CEA ADC
- 101 Solid tumors

BG-T187 — EGFRxMETxMET tsAb
- 101 Solid tumors

BG-C0902 — EGFRxMETxMET tsADC
- 101 Solid tumors

BGB-58067 — MTA Coop. PRMT5i
- 101 Solid tumors

Tarlatamab[2] — DLL3 x CD3 BiTE®
- DeLLphi-308 2L+ SCLC SubQ
- DeLLphi-310 2L+ SCLC (+B7-H3)

BG-92505 — KEAP1 activator
- 101 Solid tumors**

BON-110[3] — PD1xVEGFxCTLA4 tsAb
- 101 Solid tumors

BON-106 — *Target not disclosed*
- 101 Solid tumors**

BG-85738 — RAS(ON)i
- 101 Solid tumors

BGB-B2033 — GPC3 x 4-1BB bsAb
- 101 Solid tumors

BGB-26808 — HPK1i
- 101 Solid tumors

Xaluritamig[2] — STEAP1xCD3 BiTE®
- 20180146 mCRPC

BG-A3004 — KLRG1 mAb
- 101 Immunology and Inflammation

BGB-45035 — IRAK4 CDAC
- 101 Immunology and Inflammation

Phase 2

Sonrotoclax — BCL2i
- 103 AML
- 108 Dose ramp-up
- 203 R/R WM

Tacabrutideg — BTK CDAC
- 101 R/R CLL
- 101 R/R WM
- 102 R/R CLL
- 302 R/R CLL

Blinatumomab[2] — CD19 x CD3 BiTE®
- 20180257 R/R B-ALL SubQ, MRD+

BGB-B2033 — GPC3 x 4-1BB bsAb
- 101 3L+ HCC

BGB-B2033 — GPC3 x 4-1BB bsAb
- 201 2L+ HCC**

Tislelizumab — PD-1 mAb
- 216 1L ESCC (Q2W/Q4W)

Tarlatamab[2] — DLL3 x CD3 BiTE®
- DeLLphi-309 2L SCLC alt dosing

Phase 3

Zanubrutinib — BTKi
- 306 TN MCL
- 308 R/R MZL, R/R FL
- 309 pMN

Sonrotoclax — BCL2i
- 301 TN CLL
- 302 R/R MCL
- 303 R/R CLL
- 304 TN CLL (vs. AV)

Tacabrutideg — BTK CDAC
- 303 R/R CLL
- 304 R/R CLL (vs. Pirto)

BGB-43395 — CDK4i
- 302 1L HR+/HER2- BC

BG-C9074 — B7-H4 ADC
- 301 1L Maintenance OC

Tarlatamab[2] — DLL3 x CD3 BiTE®
- DeLLphi-305 1L ES-SCLC MTx
- DeLLphi-306 LS-SCLC
- DeLLphi-312 1L ES-SCLC Ind+MTx
- DeLLphi-315 2L ES-SCLC SubQ

Zanidatamab[4] — HER2 bsAb
- 302 1L BTC

BGB-B2033 — GPC3 x 4-1BB bsAb
- 301 2L+ HCC**

Tislelizumab — PD-1 mAb
- 310 1L UC
- 316 SubQ

Accepted submissions

Major markets (U.S., CN, EU, JP)

Sonrotoclax — BCL2i
- 201 R/R MCL (EU)

Zanubrutinib — BTKi
- 114 Tablet formulation (JP)
- 214 R/R MZL (JP)
- 306 TN MCL (CN, U.S.)

Tislelizumab — PD-1 mAb
- ZW25-301 1L HER2+ GEA (CN)

Zanidatamab[4] — HER2 bsAb
- ZW25-301 1L HER2+ GEA (CN)

- Hematology
- Lung
- Breast / Gynecological
- Gastrointestinal
- Other cancers
- Immunology and Inflammation

[1] DualityBio collaboration
[2] Amgen collaboration
[3] Huahui Health collaboration
[4] Zymeworks/Jazz collaboration

**Trial is listed on CT.gov but may not have any subjects enrolled

Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details